TMS for Anxiety: What the Research Shows in 2026

TMS for anxiety is personalized by choosing three settings for each patient: the brain target, the pulse pattern and the dose, which is set from that person's motor threshold. Most anxiety protocols use inhibitory 1 Hz or continuous theta burst stimulation over the right dorsolateral prefrontal cortex (DLPFC), while anxious depression is often treated with excitatory stimulation on the left, and Siddiqi et al. (2020, American Journal of Psychiatry) found that anxiety symptoms and low mood respond best to different stimulation sites.

TMS has a clear FDA-cleared indication for treatment-resistant depression, and a growing body of evidence for OCD. Its application to anxiety disorders sits in a middle ground: cleared for anxiety symptoms that occur alongside major depression, not cleared for generalized anxiety disorder (GAD) as a standalone diagnosis, and supported by small but consistent clinical trials and a plausible neurobiological rationale that has driven widespread off-label use.

For patients with anxiety disorders who have not responded adequately to medication or therapy, TMS is a legitimate option worth understanding in detail. The sections below cover the mechanism, how clinicians personalize the protocol, the clinical evidence, the regulatory status and the practical questions of cost, candidacy and finding a provider. For a broader overview of the device and protocols, see the transcranial magnetic stimulation treatment guide, and for the full range of options, the anxiety treatment guide.

How TMS Works for Anxiety

TMS devices generate brief, intense magnetic field pulses that pass through the skull and induce small electrical currents in the underlying cortex. Depending on the frequency and pattern of the pulses, TMS can either increase (excite) or decrease (inhibit) neural activity in the targeted region. This is not generalized brain stimulation: the effects are localized to a few centimeters of cortex directly beneath the coil, and they spread from there through connected networks.

For depression, the standard target is the left DLPFC, stimulated at high frequency (10 Hz or intermittent theta burst) to increase activity in an area that is typically underactive in depressed patients. For anxiety, the targeting logic is different and more varied across clinical protocols, which is why personalization matters more for anxiety than for routine depression treatment.

The DLPFC and Anxiety: Right vs. Left

The DLPFC plays a key role in top-down regulation of emotional responses. It modulates activity in the amygdala and other limbic structures involved in the fear response. In anxiety disorders, there is evidence of hyperactivity in right-hemisphere frontal regions and relative underactivity in the left hemisphere, a pattern roughly opposite to what is seen in depression.

Based on this asymmetry, TMS protocols for anxiety typically use one of three approaches: low-frequency (1 Hz) stimulation of the right DLPFC to inhibit overactive right frontal circuitry; high-frequency (10 Hz) stimulation of the left DLPFC to increase regulatory activity (the same target used in depression); or continuous theta burst stimulation (cTBS) of the right DLPFC for a faster inhibitory effect. The right-sided inhibitory approach has the strongest mechanistic rationale specifically for anxiety. The depression literature, which uses left-sided excitatory stimulation, contains substantial anxiety comorbidity data. Some trials have also used high-frequency right-sided stimulation, so laterality alone does not settle the protocol.

Deep TMS and the Medial Prefrontal Cortex

Deep TMS (dTMS), which uses an H-coil to reach deeper and broader cortical regions, can also target the medial prefrontal cortex (mPFC) and anterior cingulate cortex, regions directly involved in anxiety regulation. The FDA-cleared OCD protocol uses dTMS targeting the mPFC and anterior cingulate. Trials are evaluating dTMS and accelerated protocols for generalized anxiety disorder (GAD) specifically, but results specific to GAD are still limited.

How Is TMS for Anxiety Personalized?

TMS for anxiety is personalized at three levels: where to stimulate, how to stimulate and how strongly to stimulate. A psychiatrist sets each of these from the patient's diagnosis, symptom profile, comorbid conditions and response during the course. Standard depression TMS uses one fixed protocol for most patients; anxiety TMS is more individual because no single protocol has a regulatory label for GAD.

Choosing the target from the symptom profile

Target choice is the main personalization lever. Siddiqi et al. (2020) analyzed TMS outcomes in the American Journal of Psychiatry and found that "dysphoric" symptoms such as sadness and "anxiosomatic" symptoms such as anxiety, tension and insomnia improved most when stimulation hit different connected networks. Their atlas points to a dorsolateral site for mood and a more dorsomedial site for anxiety.

A follow-up pilot trial at Brigham and Women's Hospital (NCT04604210) randomized patients with depression and anxiety to the two targets using MRI-guided navigation. Symptom-specific targeting is promising, but it is not yet a validated clinical standard.

Choosing the pulse pattern and frequency

Pulse pattern decides whether the target is calmed or activated. Inhibitory 1 Hz stimulation and continuous theta burst stimulation (cTBS) are used to quiet the right DLPFC. Excitatory 10 Hz stimulation and intermittent theta burst stimulation (iTBS) are used to strengthen the left DLPFC, the usual choice when depression is present. Theta burst sessions take minutes rather than the 20 to 37 minutes of standard sessions, as described in the guide to theta burst stimulation protocols.

Setting the dose from the motor threshold

Every patient's dose is individualized at the first session. The technician or physician finds the resting motor threshold, the lowest intensity that makes the thumb twitch when the coil sits over the motor cortex, and treatment intensity is set as a percentage of it. Anxiety trials have used intensities ranging from below to above the motor threshold, for example 90% in Diefenbach et al. (2016) and 110% in Dilkov et al. (2017).

Adjusting the protocol during the course

Personalization continues after the first week. Well run practices track anxiety with validated scales such as the GAD-7, the Hamilton Anxiety Rating Scale (HAM-A) or the PCL-5 for PTSD, and review scores every one to two weeks. If anxiety does not move while mood improves, a clinician may add right-sided inhibitory stimulation or switch targets. Ask any provider how they decide when to change course.

FDA Clearance Status: What Is and Is Not Approved

Understanding the FDA clearance picture for TMS requires distinguishing between device clearances and indication clearances. TMS devices reach the market through the FDA 510(k) clearance pathway, and each clearance lists the exact conditions a device may be marketed for.

TMS is FDA-cleared for: major depressive disorder (MDD) in adults who have failed one antidepressant trial (cleared 2008, with multiple subsequent device clearances); MDD using deep TMS (cleared 2013); obsessive-compulsive disorder using deep TMS with the H7 coil (cleared 2018); and decreasing anxiety symptoms in adults with MDD who have comorbid anxiety (cleared 2021, FDA 510(k) K210201, with a second device cleared for the same indication in 2022). TMS is not specifically FDA-cleared for: generalized anxiety disorder, social anxiety disorder, PTSD, panic disorder or specific phobia when they occur without depression. TMS is legally used off-label for these conditions, and the clinical evidence for anxiety is meaningful enough that many psychiatrists and TMS practices offer it.

The 2021 clearance matters for anxious patients. According to the FDA decision summary, it was based on three randomized trials and pooled data from 11 studies in 573 patients, and it covers anxiety that accompanies depression, the most common way anxiety reaches a TMS chair. Someone with depression and significant anxiety is therefore inside a cleared indication; someone with GAD alone is not.

A few points about OCD clearance: OCD has significant anxiety features, and the FDA-cleared dTMS protocol targets brain regions (mPFC, anterior cingulate) that are also implicated in anxiety disorders. The OCD clearance does not extend to GAD or other anxiety conditions, but it demonstrates that magnetic stimulation of relevant circuits can modulate pathological anxiety. More detail is in the OCD treatment guide.

Clinical Trial Evidence for Anxiety

Generalized Anxiety Disorder

The evidence base for TMS in GAD is growing but not yet at the level of depression. Diefenbach et al. (2016, British Journal of Psychiatry, n=25) ran the first sham-controlled GAD trial, using 1 Hz right DLPFC TMS for 30 sessions, and found higher response and remission rates with active treatment. Dilkov et al. (2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry, n=40) used 20 Hz right DLPFC TMS for 25 sessions versus sham and found a large reduction in Hamilton Anxiety Rating Scale (HAM-A) scores that held at 4 weeks of follow-up. Both trials are small.

Cui et al. (2019) pooled 21 studies with 1,481 participants in a meta-analysis in General Psychiatry. rTMS produced a standardized mean difference of 0.68 in anxiety symptom reduction versus control, a medium-to-large effect, with no severe adverse events reported. Most included patients also took medication, risk of bias was moderate and heterogeneity was high. Evidence grade: Moderate.

Anxiety as a Depression Comorbidity

The largest body of data on TMS and anxiety comes from depression treatment, where anxiety symptoms are measured as secondary outcomes. The pivotal multisite depression trial that supported the 2008 clearance (O'Reardon et al., 2007, Biological Psychiatry, n=301) established TMS for depression itself. Clarke et al. (2019, Journal of Affective Disorders) then followed 248 patients with treatment-resistant depression, 172 of whom had one or more anxiety disorders, and found significant reductions in HAM-A scores for every anxiety diagnosis, with depression outcomes similar to patients without anxiety. That study had no sham group.

PTSD: Emerging Evidence

PTSD is one of the most active research areas for TMS outside of depression. A meta-analysis by Cirillo et al. (2019, Brain and Behavior) reviewed nine PTSD studies and found a large pooled effect favoring TMS, though trials used different targets, frequencies and session counts. The US Department of Veterans Affairs has funded trials of TMS and theta burst stimulation for veterans with PTSD. Evidence grade: Emerging. The PTSD treatment guide covers the other options.

The Stanford SAINT Protocol and Accelerated TMS

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, also called Stanford Neuromodulation Therapy (SNT), gained attention after a double-blind trial in the American Journal of Psychiatry (Cole et al., 2022, n=29) reported a 78.6% remission rate in treatment-resistant depression after 5 days of intensive TMS. This compares to remission rates of 30% to 50% with standard TMS over 6 weeks. SAINT uses individualized targeting based on fMRI connectivity mapping, a high total dose of intermittent theta burst stimulation and 10 sessions per day for 5 days (versus 1 session per day for 36 days in standard protocols).

SAINT is the clearest example of personalized TMS: each patient's target is chosen from their own brain scan rather than a scalp measurement. The SAINT trial was designed and scored around depression, and anxiety was not its primary outcome. SAINT received FDA Breakthrough Device designation and a 510(k) clearance (for MDD) in 2022. It is not yet widely available and costs considerably more than standard TMS. For anxiety specifically, SAINT-like accelerated protocols are being studied but are not yet standard of care.

TMS vs. Medication for Anxiety: A Comparison

TMS is not a first-line treatment for anxiety. The standard approach is cognitive behavioral therapy (CBT), which has the strongest evidence base across anxiety disorders, often combined with an SSRI or SNRI. TMS becomes relevant for patients who have not responded adequately to these first-line approaches, who cannot tolerate medication side effects, or who have significant depression comorbidity alongside their anxiety. Other options people compare at this stage include ketamine for anxiety, neurofeedback and biofeedback, each with its own evidence gaps.

What a TMS Course Looks Like: Practical Details

Standard TMS for anxiety follows a similar structure to depression protocols. A typical course involves:

• Initial psychiatric evaluation to confirm diagnosis, rule out contraindications, and determine targeting approach
• Motor threshold assessment (a brief calibration procedure to set the stimulation intensity for each individual)
• 36 sessions of 20 to 37 minutes each, delivered Monday through Friday over 6 to 9 weeks; theta burst sessions are much shorter, and Blumberger et al. (2018, The Lancet, THREE-D trial) found iTBS noninferior to 10 Hz stimulation for depression
• Each session involves sitting in a chair with the TMS coil placed against the head; patients are awake and can talk during treatment, and they can drive home afterward because no sedation is used
• Mild scalp discomfort or headache during or after treatment is the most common side effect, typically managed with acetaminophen
• Booster sessions may be offered if symptoms return after an initial response

Contraindications include metal implants in or near the head (cochlear implants, aneurysm clips, metal skull plates), history of seizures, and certain cardiac devices. TMS is generally safe in patients with metal dental work or braces, as these are outside the field range of the coil. The evaluation should also cover medications that lower the seizure threshold, alcohol use and bipolar disorder, because these change how a clinician sets the protocol.

Who Is a Good Candidate for TMS for Anxiety?

The strongest candidates are adults whose anxiety comes with major depression and who have not improved after at least one antidepressant, because that group sits inside an FDA-cleared indication and is most likely to have insurance coverage. Adults with GAD who have tried CBT and at least one or two medications without enough relief are reasonable off-label candidates. People with PTSD or OCD features may also be considered, with the protocol chosen for that diagnosis.

TMS is a poorer fit for people with untreated seizure disorders, metal in the head, active substance withdrawal or anxiety that has not yet had a fair trial of therapy. Panic disorder is a weaker case: a 2022 meta-analysis in the Annals of Clinical Psychiatry found improvement in GAD but not significant improvement in panic severity.

Who delivers TMS for anxiety?

TMS is prescribed by a psychiatrist or another licensed prescriber, often a psychiatric nurse practitioner, and delivered by a trained TMS technician under that clinician's supervision. For anxiety, ask who chooses the target, whether they use neuronavigation or a scalp method, which anxiety scale they track and how often a physician reviews progress. A practice that answers these plainly is easier to judge than one that only lists session prices.

To compare providers, browse TMS clinics across the US and filter by state. Listing order on Regenerated.com is not paid ranking, Featured slots are labeled and capped, Verified means credential checks rather than spend, and the directory is free for patients. Inclusion in the directory is not an endorsement, so confirm each clinic's psychiatric oversight and protocols yourself.

Insurance Coverage and Cost Realities

Insurance coverage for TMS is most reliable when the primary diagnosis is major depressive disorder and there is documented failure of at least one antidepressant. For anxiety as a primary indication, coverage is inconsistent and often requires appeals. Many practices offer TMS for anxiety under a depression comorbidity framework if that diagnosis is present, which is common given how frequently depression and anxiety co-occur. The 2021 clearance for anxiety symptoms within MDD gives that framework a clearer regulatory basis.

Out-of-pocket costs for a full 36-session course run $7,200 to $14,400 at $200 to $400 per session. Some practices offer sliding scale fees or payment plans. Personalized options such as MRI-guided neuronavigation or accelerated fMRI-targeted protocols usually add cost, so ask what is included before starting. The cost comparison that matters for treatment-resistant patients is not TMS versus generic SSRIs, but TMS versus ongoing medication management, psychiatric visits, and the indirect costs of inadequately treated anxiety over months or years. A fuller breakdown is in the TMS therapy cost guide.

The Bottom Line

TMS is a legitimate, evidence-supported treatment option for anxiety, particularly for patients with treatment-resistant GAD, PTSD, or anxiety comorbid with depression. The evidence is not as strong or as extensively replicated as it is for MDD, and the lack of a specific FDA clearance for GAD means insurance coverage is harder to obtain without a depression diagnosis. The clinical trial data are consistent, and the safety profile favorable, which makes off-label use in carefully selected patients reasonable.

If you are considering TMS for anxiety, the most important step is finding a TMS provider with psychiatric expertise who can evaluate whether your anxiety subtype and history make you a good candidate, and who will specify which target, pulse pattern and dose they use and why. The neurobiological rationale for TMS in anxiety is solid. Applying it to your situation takes clinical judgment from someone who has examined you, and the national directory of transcranial magnetic stimulation providers is a starting point for finding one.

Frequently asked questions

How is TMS treatment personalized for anxiety?

TMS for anxiety is personalized by choosing the brain target, the pulse pattern and the intensity for each patient. Most anxiety protocols inhibit the right dorsolateral prefrontal cortex with 1 Hz or continuous theta burst stimulation, while anxious depression often gets left-sided 10 Hz or iTBS. Intensity is set from each person's motor threshold, and some practices use MRI or fMRI navigation to place the coil. Progress is tracked with scales such as the GAD-7.

Is TMS FDA approved for anxiety?

TMS is FDA-cleared for anxiety symptoms only when they occur alongside major depression. That clearance came in 2021 through the 510(k) pathway and covers adults with MDD who did not improve on an antidepressant. TMS is not cleared for generalized anxiety disorder, panic disorder, social anxiety or PTSD on their own, so treatment for those conditions is off-label and insurance coverage is less likely.

How many TMS sessions does anxiety take?

A standard TMS course for anxiety follows the depression schedule of about 36 sessions, five days a week over 6 to 9 weeks. GAD trials have used fewer sessions, for example 25 in Dilkov et al. (2017) and 30 in Diefenbach et al. (2016). Accelerated protocols compress treatment into about 5 days with several sessions per day, but they are studied mainly in depression and are not widely available.

Which side of the brain does TMS target for anxiety?

TMS for anxiety most often targets the right dorsolateral prefrontal cortex with inhibitory stimulation, because anxiety is linked to overactivity in right frontal regions. When depression is also present, clinicians often stimulate the left DLPFC instead or in addition. Siddiqi et al. (2020) found that anxiety and tension improve most with a more dorsomedial target, which some research centers now test with MRI-guided placement.

How much does TMS for anxiety cost without insurance?

TMS for anxiety typically costs $200 to $400 per session without insurance, or $7,200 to $14,400 for a full 36-session course. Personalized add-ons such as MRI-guided navigation and accelerated protocols usually cost more. Insurance is most likely to pay when anxiety comes with major depression that has not responded to an antidepressant, so ask the practice to check your benefits before the first session.

Does TMS for anxiety work better than medication?

TMS has not been shown to work better than medication for anxiety, because few trials compare them directly. Meta-analyses such as Cui et al. (2019) show a medium-to-large effect versus control, but most of those patients also took medication. TMS avoids systemic side effects like sedation and dependence, which makes it worth discussing when SSRIs, SNRIs or CBT have not helped enough. See the generalized anxiety disorder treatment guide for the full set of options.